<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03814291</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI302A101</org_study_id>
    <nct_id>NCT03814291</nct_id>
  </id_info>
  <brief_title>A Dose Escalation Study of IBI302 in Patients With Wet Age-related Macular Degeneration</brief_title>
  <official_title>A Dose Escalation Phase I Clinical Study to Evaluate the Tolerability and Safety of IBI302 in Patients With Wet Age-related Macular Degeneration (AMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed for single-center, open-label, dose escalation phase I trial to
      evaluate the safety and tolerability of a single intravitreal injection of IBI302 in patients
      with wet AMD.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 16, 2019</start_date>
  <completion_date type="Anticipated">April 5, 2020</completion_date>
  <primary_completion_date type="Anticipated">February 21, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety evaluation indicators</measure>
    <time_frame>Baseline to Day43</time_frame>
    <description>Decreasing of BCVA; b) Changes in intraocular pressure compared with baseline; c) Incidence, relatedness and severity of all adverse events, treatment emergent adverse events and serious adverse events;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy evaluation indicators</measure>
    <time_frame>Baseline to Day43</time_frame>
    <description>Changes in central subfield thickness by OCT compared with baseline; b) Changes in CNV area by FA compared with baseline; c) Changes in BCVA compared with baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity evaluation indicators</measure>
    <time_frame>Baseline to Day43</time_frame>
    <description>Positive rate of anti-drug antibody and neutralizing antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The area under the drug-time curve from 0 to time t (AUC0-t)</measure>
    <time_frame>Baseline to Day43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The area under the curve at the time of 0-infinity (AUC0-∞)</measure>
    <time_frame>Baseline to Day43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The peak concentration (Cmax)</measure>
    <time_frame>Baseline to Day43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The peak time (Tmax)</measure>
    <time_frame>Baseline to Day43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance rate (CL)</measure>
    <time_frame>Baseline to Day43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (t1/2)</measure>
    <time_frame>Baseline to Day43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free and total VEGF concentration</measure>
    <time_frame>Baseline to Day43</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Neovascular Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>cohort 1 IBI302 treated with first dose level of IBI302</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 2 IBI302 treated with second dose level of IBI302</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 3 IBI302 treated with third dose level of IBI302</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 4 IBI302 treated with fourth dose level of IBI302</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 5 IBI302 treated with fifth dose level of IBI302</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>cohort 6 IBI302 treated with sixth dose level of IBI302</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI302</intervention_name>
    <description>0.05mg/eye;Intraocular injection</description>
    <arm_group_label>cohort 1 IBI302 treated with first dose level of IBI302</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI302</intervention_name>
    <description>0.15mg/eye;Intraocular injection</description>
    <arm_group_label>cohort 2 IBI302 treated with second dose level of IBI302</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI302</intervention_name>
    <description>0.5mg/eye;Intraocular injection</description>
    <arm_group_label>cohort 3 IBI302 treated with third dose level of IBI302</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI302</intervention_name>
    <description>1mg/eye;Intraocular injection</description>
    <arm_group_label>cohort 4 IBI302 treated with fourth dose level of IBI302</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI302</intervention_name>
    <description>2mg/eye;Intraocular injection</description>
    <arm_group_label>cohort 5 IBI302 treated with fifth dose level of IBI302</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI302</intervention_name>
    <description>4mg/eye;Intraocular injection</description>
    <arm_group_label>cohort 6 IBI302 treated with sixth dose level of IBI302</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patient ≥ 50 yrs. of age.

          2. Active subfoveal CNV secondary to wet AMD, with lesion size ≤ 12 optic discs in the
             study eye.

          3. BCVA score of 10-73 letters using ETDRS charts (in 4 meters) in the study eye.

          4. Central macular sub-field thickness according to OCT of at least 250 micron.

          5. Clear stereoscopic fundus photography is obtained while the lens or other media is
             clear.

          6. Female subjects of childbearing age or male subjects with childbearing age female
             partner agree to take effective contraceptive measures from the screening period to 3
             months after the end of treatment.

          7. Willing and able to sign informed consent form and comply with visit and study
             procedures per protocol.

        Exclusion Criteria:

          1. Presence of other causes of CNV other than wet AMD in the study eye.

          2. Presence of active diabetic retinopathy in the study eye.

          3. Presence of uncontrolled glaucoma in the study eye (defined as IOP≥30mmHg despite the
             standardized treatment).

          4. Prior retinal detachment in the study eye.

          5. Prior any treatment of following in the study eye:

               1. Anti-VEGF therapy within 6 months prior to screening;

               2. Anti-complement therapy;

               3. Laser photocoagulation;

               4. Photodynamic therapy;

               5. Transpupillary thermotherapy

               6. Intraocular surgery;

               7. Intraocular or periocular glucocorticoid injection therapy within 6 months prior
                  to enrollment;

          6. Presence of any non-AMD disease that may affect visual acuity in the study eye

          7. Prior anti-VEGF therapy within 1 month before study drug administration or plan of
             above anti-VEGF therapy in the non-study eye during the whole study.

          8. Oral steroid drugs within 1 month before study drug administration.

          9. Presence of active intraocular or periocular inflammation or infection.

         10. Diabetic patients have any of the following conditions:

               1. Microvascular and macrovascular complications;

               2. HbA1c&gt;7.5% when screening;

               3. Receiving more than two oral hypoglycemic agents;

               4. Receiving insulin or GLP-1 receptor agonist;

         11. Hypertension (defined as systolic blood pressure &gt;140 mmHg or diastolic blood pressure
             &gt;90 mmHg despite standard treatment);

         12. Presence of any following laboratory abnormality:

               1. PLT&lt;100×109/L, INR≥1.5ULN, APTT≥ 10 seconds more than ULN;

               2. ALT or AST &gt;2ULN;

               3. Cr or Ur&gt;1.5ULN;

         13. Large or medium surgery, or unhealed surgical incisions, ulcers or fractures within 1
             month before study drug administration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shanghai General Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>January 15, 2019</study_first_submitted>
  <study_first_submitted_qc>January 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 24, 2019</study_first_posted>
  <last_update_submitted>February 10, 2020</last_update_submitted>
  <last_update_submitted_qc>February 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulin Fc Fragments</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

